The purpose of this study is to find out if VIT-2763 an experimental drug being developed by Vifor, the sponsor of this study, is safe for the treatment of improving iron deficiency in sickle cell diseased subjects. That means it can prevent hemolysis (the breakdown of red blood cells) and pain crisis in patients with sickle cell disease. You will be receiving VIT-2763 or placebo (study medication). A placebo looks like VIT-2763 in a capsule, but does not contain any active substance.

The total duration of your participation in the study will be up to 16 weeks. This involves a screening period of up to 4-weeks (28 days) during which the study doctor will check whether you can participate, 8 weeks of treatment and a 4-week follow-up after the treatment. You will have at least 7 visits(V1-V7) to the study site similar to a standard of care visit and may include 12-lead ECG and assessments of pain episodes.

This study will assess the appropriate dosing and evaluate the safety of NDec in patients with sickle cell disease. Patients may or may not be currently treated with Hydroxyurea to participate in this study. This study is for male and female patients above the age of 18 years who weight between 110 to 308 pounds. Patients must experience at least 2 but no more than 10 Vaso-occlusive crises within a 12-month period. This is an oral medication that is take twice a week and they will participate in this study for approximately 52 weeks.

Researchers want to find out more about how to manage and treat suspected infections and sepsis. Sepsis is a life-threatening condition in which your body is fighting a severe infection.

This study is a collection of health information, blood samples and possibly a nose swab. The samples collected will depend on your doctor's recommendation.

The purpose of this study is determine the optimal dose, efficacy and safety of an investigational drug (a new drug not yet approved by the U.S. Food and Drug Administration) in adults with Advanced Systemic Mastocytosis. The investigational drug is known as CGT9486 and will be taken daily orally. Participation in the study is expected to be approximately 6 years.

The purpose of this study is to compare the safety and efficacy of the PMX cartridge ( Toramyxin) (in Addition to Standard Medical Care for Patients with Endotoxemic Septic Shock:
Eligible and consented subjects will be randomized to receive either the PMX cartridge (administered twice for 1½ to 2 hours per treatment session approximately 24 hours apart) plus standard medical care or standard medical care alone. For all subjects in whom treatment has been initiated, a follow-up visit (if they are still in the hospital) or a telephone call will be completed at Day 28 (or later) to determine their mortality status. In surviving subjects, a follow-up visit or telephone call to determine their mortality status will also take place at approximately three months (i.e. Day 90) and 12 months after the subject was randomized.

This study is for participants who have been diagnosed with a pulmonary embolism or PE. A PE is a blood clot in the lung. This study is comparing the FlowTriever Retrieval/Aspiration System to any commercially available Catheter Directed Thrombolysis system in participants who have a PE and undergo a procedure to remove the clot. Participants will be randomized which means they will be randomly assigned like the flip of a coin to have the procedure done wit the the FlowTriever system or a CDT system. All of the devices being used in this study are FDA approved for this indication. This study involves collecting data from the time of diagnosis through 30 days post procedure. Study participation will last about 30 days.